Of note, 5 out of the 6 patients tested had hormone receptor-positive (HR+) and 1 had HR + HER2+ breast cancer, suggesting that T cell dysfunction is common in HR+ breast cancer. This evidence concerns the gene ERBB2 and breast carcinoma.